GleamWall
中文EN

PMN ProMIS Neurosciences Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1374339 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY62.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-152.3%
ROA-113.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio8.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio7.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$6.71M$9.52M$6.97M$9.37M$9.80M$8.75M$5.46M$4.32M
SG&A expense$1.91M$2.74M$1.67M$1.40M$1.95M$1.43M$2.00M$1.68M
Operating income-$8.62M-$12.27M-$8.64M-$10.77M-$11.75M-$10.18M-$7.46M-$6.00M
Net income-$8.16M-$11.73M-$8.24M-$10.67M-$11.58M-$10.12M-$7.35M-$238,207
EPS (basic)-0.89-1.28-1.26—-5.93-7.26-5.27—
EPS (diluted)-0.89-1.28-1.26—-5.93-7.26-5.27—
Weighted avg. shares (diluted)9.14M9.14M6.53M—1.95M1.39M1.39M—
Balance sheet
Cash & equivalents$44.07M$53.43M$63.81M$6.12M$15.40M$4.51M$8.36M$13.29M
Short-term investments$33,753$33,753$33,753$33,753$33,051$33,051$33,051$33,051
Current assets$47.16M$56.69M$65.61M$9.18M$21.46M$9.51M$13.65M$18.91M
Total assets$47.16M$56.69M$67.41M$9.18M$21.46M$9.51M$13.65M$18.91M
Current liabilities$5.34M$7.22M$6.61M$10.41M$12.21M$9.82M$4.06M$2.22M
Total liabilities$5.40M$7.29M$6.69M$10.44M$12.27M$9.89M$4.17M$2.42M
Shareholders' equity$41.76M$49.40M$60.72M-$1.26M$9.19M-$382,579$9.47M$16.49M
Shares outstanding8.97M8.97M8.97M2.15M53.81M32.69M32.69M1.31M
Cash flow statement
Operating cash flow-$9.38M-$10.39M-$12.38M-$9.28M-$10.06M-$3.85M-$4.93M-$8.72M
Financing cash flow$21,072$0$70.08M-$1———$469,999
Stock-based compensation$482,640$408,895$189,425$203,171$197,147$212,015$245,295$623,189

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.